Found 12 results for Small Cell Lung Cancer
A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Rapid Autopsy Protocol for Patients with Small Cell Lung Cancer
S
Shadia Jalal, MD
This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection. This proposal is a collaboration between scientists, lung cancer physicians, pathologists, and the IUSCCC Translational Research Core. …
A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
R
Rohan Maniar
What is the purpose of this study?This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC …
Phase I/II Trial of Lurbinectedin with Osimertinib in Transformed Small Cell Lung Cancer
M
Misty D. Shields, MD, PhD
Primary Objective:To assess the efficacy of the combination of lurbinectedin with osimertinib in patients with EGFR altered non-small cell lung cancer (NSCLC) with documented transformation to SCLC, after the use of EGFR tyrosine kinase inhibitor osimertinib.Secondary ObjectiveTo evaluate the safety of the combination of lurbinectedin with osimertinib in patients with …
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
N
Nasser Hanna, MD
This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease). Interested in participating? For more information about this research study or other cancer-related …
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer
T
Tim Lautenschlaeger
There has been evidence that patients being treated with chemoradiation for Non-Small Cell Lung Cancer (NSCLC) have experienced cardiac toxicities (heart damage). This study is exploring if testing patients hearts that have been diagnosed with NSCLC before and after treatment can help investigators decrease heart damage for patients in the …
Exploring Treatment Options After Lung Cancer Surgery
V
Vijaya L. Kakani, MD
Do you have non-small cell lung cancer (NSCLC) but the cancer was not fully removed by surgery? You may qualify for a study exploring treatment options for NSCLC.This research study is testing whether adding a medication called sacituzumab tirumotecan to pembrolizumab after surgery may help prevent non-small cell lung cancer …
An Open-Label, Randomized Study of Bms-986489 (Atigotatug + Nivolumab Fixed-Dose Combination) Vs Durvalumab as Consolidation Therapy Following Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (Tigos-Ls)
M
Misty D. Shields, MD, PhD
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:Evaluate the efficacy of BMS-986489 vs durvalumabEvaluate the safety profile of BMS-986489Interested in participating? For more information about this research study or …
Together for Tomorrow: Explore New Treatment Options for Lung Cancer
V
Vijaya L. Kakani, MD
We understand that living with non-small cell lung cancer (NSCLC), especially with the KRAS G12C mutation, can be incredibly challenging. Many people with lung cancer go through hard treatments and tough side effects. That's why we're inviting adults (ages 18 and older) who have advanced or metastatic nonsquamous NSCLC to participate …
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of Tng462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with Mtap Loss and Ras Mutation
A
Anita Turk, MD
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with the following agents: RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab-paclitaxel. Overall, the study comprises a dose escalation phase and a dose expansion phase.Interested in participating? For …
A Randomized Phase Ii/Iii Study of Docetaxel and Ramucirumab with or Without Cemiplimab (Regn2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage Iv or Recurrent Non-Small Cell Lung Cancer (Lung-Map Non-Matched Sub-Study)
R
Rohan Maniar
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody …
1 - 10 of 12
- 1
- 2
Please choose between Voice or SMS based delivery of verification code
or